Accessibility Menu
Neuphoria Therapeutics logo

Neuphoria Therapeutics(NASDAQ) NEUP

Market Cap$20.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-43%
5 YearN/A
1 Year-56%
1 Month-14%
$3.83
+0.53%
+0.02Today
Neuphoria Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 3.802026-07-29
Neuphoria Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+14.11%USD 3.332026-07-22
1 month-13.64%USD 4.402026-06-29
3 month-27.89%USD 5.272026-04-30
Year to date-2.06%USD 3.882025-12-31
1 year-55.61%USD 8.562025-07-29
3 year-83.42%USD 22.922023-07-28
Since inception-42.53%USD 6.632024-12-24

Neuphoria Therapeutics Financials at a Glance

Market Cap

$20.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

-$10.47M

Net Income (TTM)

-$28.48M

EPS (TTM)

$0.00

P/E Ratio

-0.16

Dividend

$0.00

Beta (Volatility)

0.64 (Low)

Price

$3.83

Volume

822

Open

$3.85

Previous Close

$3.80

Daily Range

$3.77 - $3.92

52-Week Range

$3.19 - $21.40

Estimated Earnings Date

Sep 2, 2026

NEUP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neuphoria Therapeutics

Neuphoria develops medicines for people with anxiety and trauma-related disorders. Its main drug aims to help those with social anxiety or post-traumatic stress. The company’s work targets patients who need fast, non-addictive relief from mental health symptoms.

Brainy Business: Products and Services

  • BNC210 (Lead Drug): Oral treatment for social anxiety and post-traumatic stress; nearly all revenue in 2025 came from licensing milestones.
  • Early-Stage CNS Pipeline: Drugs for cognitive problems in Alzheimer’s disease, developed with Merck; received milestone revenue in 2025.
  • Preclinical Programs: Next-generation compounds for brain disorders; not yet generating revenue.
  • Cancer Stem Cell Technology: Licensed to Carina Biotech; milestone payments contributed less than 5% of revenue in 2025.

Growth Spurts: Expansion and Alliances

  • Redomiciled from Australia to the US in December 2024, becoming a Delaware-based company.
  • Formed a strategic partnership with Merck for Alzheimer’s drug development, with milestone payments in 2025.
  • Licensed cancer stem cell technology to Carina Biotech in October 2024, earning a milestone payment.
  • Launched Phase 3 clinical trials for BNC210 in social anxiety and PTSD in 2025.
  • Established an at-the-market equity facility in November 2024 to raise up to $3.56 million.

What Makes Neuphoria Stand Out

Neuphoria focuses on brain drugs that avoid sedation and addiction, unlike many current treatments. Its main revenue comes from partnerships, not product sales. The company’s small size allows for targeted research spending and quick strategic shifts.

Five Things You Need to Know

  • Revenue was $15.0 million in Q1 2025, up from $0 in Q1 2024.
  • Net income reached $11.26 million in Q1 2025, reversing a prior loss.
  • Cash and equivalents totaled $17.04 million as of March 31, 2025.
  • Operating expenses fell 11.7% year-over-year for the nine months ending March 2025.

Bottom Line

Neuphoria has shifted from an Australian biotech to a US-based, partnership-driven company. Its focus on licensing and milestone payments shapes its financial profile and future direction.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Spyridon Papapetropoulos, MD, PhD

Website

www.neuphoriatx.com

Headquarters

Burlington, MA 01803, US

NEUP Financials

Key Financial Metrics (TTM)

Gross Margin

104.75%

Operating Margin

230.73%

Net Income Margin

271.97%

Return on Equity

-113.35%

Return on Capital

-3.88%

Return on Assets

-81.82%

Earnings Yield

-6.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.40M

Volume

822

Avg. Volume

198.76K

Financials (TTM)

Gross Profit

-$10.97M

Operating Income

-$24.16M

EBITDA

-$22.73M

Operating Cash Flow

$59.46M

Capital Expenditure

-$3.00

Free Cash Flow

$59.46M

Cash & ST Invst.

$19.44M

Total Debt

$34.23K

Neuphoria Therapeutics Performance Analysis

Neuphoria Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 191,210N/A
20232023-06-30USD 0N/A
20242024-06-30USD 0N/A
20252025-06-30USD 15,649,448N/A
Neuphoria Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30-169.8%
Q12025-09-30100.0%
Q22025-12-31N/A
Q32026-03-31N/A
Neuphoria Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.14N/A
20232023-06-30USD -0.12-16.1%
20242024-06-30USD -223.38190014.3%
20252025-06-30USD -0.23-99.9%
Neuphoria Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30-171.0%
Q12025-09-30-43.4%
Q22025-12-3188.5%
Q32026-03-3187.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$165.70K

-101.1%

Gross Margin

0.00%

N/A

Market Cap

$20.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.57M

N/A

Employees

8

N/A

Net Income

-$505.06K

-104.5%

EBITDA

-$1.00M

-108.3%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$19.44M

+14.1%

Total Debt

$34.23K

-80.2%

Accounts Receivable

$1.61M

+6427.9%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$34.23K

-77.7%

Return on Assets

-81.82%

N/A

Return on Invested Capital

-72.57%

N/A

Free Cash Flow

-$3.87M

-133.8%

Operating Cash Flow

-$3.87M

-133.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IINNInspira Technologies Oxy B.H.N. Ltd.
$0.87-8.71%
LFWDLifeward Ltd.
$7.10+2.13%
CHEKCheck-Cap Ltd.
$1.86+1.64%
ALZNAlzamend Neuro Inc
$1.34+2.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About NEUP

What is the current price of Neuphoria Therapeutics?

Neuphoria Therapeutics is trading at $3.80 per share.

What is the 52-week range for Neuphoria Therapeutics?

Over the past 52 weeks, Neuphoria Therapeutics has traded between $3.19 and $21.40.

How much debt does Neuphoria Therapeutics have?

As of the most recent reporting period, Neuphoria Therapeutics reported total debt of $34.23K.

How much cash does Neuphoria Therapeutics have on hand?

Neuphoria Therapeutics reported $19.44M in cash and cash equivalents in its most recent financial results.

What is Neuphoria Therapeutics’s dividend yield?

Neuphoria Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services